Nuclear Medicine Software Market Size to Hit USD 1884.45 Million by 2033

Nuclear Medicine Software Market Size, Share, Growth Trends, Segmental Analysis, Leading Company Profiles: By Software Type (Image Processing and Analysis Software, Patient Data Management Software, AI and Advanced Analytics Software, Dosimetry and Treatment Planning Software, Workflow Management and Reporting Software, PACS and Archiving Integration Software, Others), By Modality (PET Software, SPECT Software, PET/CT Software, SPECT/CT Software, Others), By Functionality/Workflow (Image Acquisition and Reconstruction, Image Processing and Visualization, Quantitative Analysis and Biomarker Extraction, Dosimetry and Treatment Planning, Reporting and Documentation, Others), By Therapeutic Area (Oncology, Cardiology, Neurology, Thyroid Disease, Others), By Deployment Mode (On-Premises, Cloud-Based, Hybrid), By End User (Hospitals and Academic Medical Centers, Diagnostic Imaging Centers, Nuclear Medicine Specialty Clinics, Research and Academic Institutions, Others), By Region (North America [United States, Canada, Mexico], Europe [Germany, United Kingdom, France, Netherlands, Sweden, Rest of Europe], Asia-Pacific [Japan, China, India, South Korea, Australia, Rest of Asia-Pacific], Latin America [Brazil, Argentina, Rest of Latin America], Middle East & Africa [UAE, Saudi Arabia, South Africa, Rest of MEA]) and Market Forecast, 2026 – 2033

  • Published: May, 2026
  • Report ID: 376
  • Pages: 160+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Nuclear Medicine Software Market Size to Hit USD 1884.45 Million by 2033

(An Updated Version is Available)

1. Introduction

  • 1.1 Report Overview and Scope

  • 1.2 Market Definition

  • 1.3 Study Assumptions and Limitations

  • 1.4 Research Methodology

  • 1.4.1 Primary Research Approach

  • 1.4.2 Secondary Research Approach

  • 1.4.3 Data Triangulation and Validation

  • 1.5 List of Abbreviations and Acronyms

2. Executive Summary

  • 2.1 Market Snapshot and Key Highlights

  • 2.2 Key Market Findings and Strategic Insights

  • 2.3 Market Attractiveness Analysis by Segment

  • 2.4 Analyst Recommendations

3. Market Overview

  • 3.1 Definition and Introduction to Nuclear Medicine Software

  • 3.2 Market Taxonomy and Scope

  • 3.3 Historical Market Evolution (2021–2025)

  • 3.4 Nuclear Medicine Software Ecosystem Overview

  • 3.4.1 Role of Software in PET and SPECT Imaging Workflows

  • 3.4.2 Image Acquisition, Reconstruction, and Advanced Quantification Pipelines

  • 3.4.3 Dosimetry Planning and Radiopharmaceutical Management Software

  • 3.4.4 Theranostics Software Integration: Diagnostics-to-Therapy Clinical Pathway

  • 3.4.5 AI-Powered Image Analysis and Clinical Decision Support in Nuclear Medicine

  • 3.4.6 PACS Integration, Cloud-Based Data Sharing, and Interoperability Frameworks

  • 3.5 Value Chain Analysis

  • 3.5.1 Research and Development (AI Algorithms, Image Reconstruction, Deep Learning Models)

  • 3.5.2 Manufacturing and Software Development (Coding, Testing, Regulatory Compliance, PACS Integration)

  • 3.5.3 Sales, Distribution, and Channel Management (Hospital IT Procurement, GPOs, OEM Partnerships)

  • 3.5.4 Post-Sale Services (Technical Support, Software Updates, User Training)

  • 3.5.5 End Users (Hospitals and Clinics, Diagnostic Imaging Centers, Academic Institutes, Pharma Companies)

  • 3.6 Regulatory and Policy Framework

  • 3.6.1 U.S. FDA 510(k) Clearance and De Novo Pathways for Nuclear Medicine SaMD (Software as a Medical Device)

  • 3.6.2 EU MDR (EU 2017/745) CE Mark Requirements for Nuclear Medicine Software (Class IIa and IIb)

  • 3.6.3 IAEA Guidelines for Nuclear Medicine Quality Management and Radiation Safety

  • 3.6.4 CMS Reimbursement Policies: Pass-Through Payments for PET and SPECT Procedures

  • 3.6.5 U.S. NRC and Agreement State Licensing for Nuclear Medicine Facilities

  • 3.6.6 Asia-Pacific Regulatory Landscape (PMDA Japan, NMPA China, CDSCO India)

  • 3.7 Macroeconomic Factors Influencing Market Growth

  • 3.7.1 Rising Global Cancer Burden: 20 Million New Cases Globally in 2022 (WHO)

  • 3.7.2 Cardiovascular Disease Prevalence: 19.8 Million Deaths in 2022, 32% of All Deaths (WHO)

  • 3.7.3 Neurological Disorder Growth: Increasing Alzheimer's, Parkinson's, and Dementia Imaging Volumes

  • 3.7.4 Government Investment in Healthcare Digitalization and Nuclear Medicine Expansion

  • 3.7.5 Radiopharmaceutical R&D Investment (Eli Lilly, Sanofi, Novartis) Driving Downstream Software Demand

4. Market Dynamics

  • 4.1 Key Market Drivers

  • 4.1.1 Rising Prevalence of Cancer and Cardiovascular Diseases Driving PET and SPECT Imaging Volumes

  • 4.1.2 Integration of AI and Machine Learning (CNNs, GANs) Enhancing Image Reconstruction and Diagnostic Accuracy

  • 4.1.3 Rapid Adoption of Hybrid Imaging Technologies (PET/CT, SPECT/CT, PET/MRI) Requiring Advanced Software Support

  • 4.1.4 Expanding Theranostics Programs (Lu-177 PSMA, Lu-177 DOTATATE) Generating Dosimetry and Therapy Planning Software Demand

  • 4.1.5 Growing Adoption of Cloud-Based Nuclear Medicine Platforms for Remote Access and Scalability

  • 4.1.6 SNMMI AI-Powered Global Radiopharmaceutical Trial Finder Launch (Ancora.ai Platform, August 2025)

  • 4.1.7 FDA 510(k) Clearances for New Nuclear Medicine Software Platforms (DOSIsoft PLANET Onco Dose v3.2, March 2025; Bracco HeartSee v4.0, March 2026)

  • 4.2 Market Restraints

  • 4.2.1 High Cost of Nuclear Medicine Software Deployment and Licensing in Resource-Constrained Settings

  • 4.2.2 Data Security Concerns and Healthcare IT Privacy Compliance Challenges (HIPAA, GDPR)

  • 4.2.3 Lack of Seamless Interoperability with Existing Hospital EHR, PACS, and RIS Systems

  • 4.2.4 Shortage of Skilled Nuclear Medicine Technologists and Medical Physicists for Software Operation

  • 4.3 Market Opportunities

  • 4.3.1 AI-Augmented Dosimetry and Quantification Software for Personalized Radioligand Therapy (RLT)

  • 4.3.2 SaaS and Subscription-Based Pricing Models Creating Recurring Revenue and Accessibility for Smaller Centers

  • 4.3.3 Digital Pathology Convergence and Multimodality Analytics Platforms for Precision Oncology

  • 4.3.4 Expansion of Nuclear Medicine Software in Emerging Markets (Asia Pacific, Latin America, MEA)

  • 4.3.5 AIIMS New Delhi–SAMEER MOU for Medical Electronics and Nuclear Medicine IT Innovation (March 2025)

  • 4.3.6 Claritas NucMed Technologies Ltd. Spin-Off: Commercializing AI PET/SPECT Software Globally (July 2024)

  • 4.4 Market Challenges

  • 4.4.1 Regulatory Complexity and Multi-Jurisdiction Compliance (FDA 510(k), EU MDR, PMDA, NMPA) for Global Launches

  • 4.4.2 Resistance to Digital Transition in Traditional Nuclear Medicine Departments

  • 4.4.3 Managing Big Data from Hybrid Imaging Systems and AI Analytics Pipelines at Scale

  • 4.4.4 Customization Limitations: Lack of Region-Specific Regulatory Compliance Modules in Off-the-Shelf Software

5. Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers (Algorithm Developers, Cloud Infrastructure Providers, AI Chip Manufacturers)

  • 5.2 Bargaining Power of Buyers (Hospital Systems, GPOs, Academic Medical Centers, Radiopharma Companies)

  • 5.3 Threat of New Entrants

  • 5.4 Threat of Substitutes (General-Purpose PACS Platforms, Radiology AI SaaS Providers)

  • 5.5 Intensity of Competitive Rivalry

6. PESTEL Analysis

  • 6.1 Political Factors

  • 6.2 Economic Factors

  • 6.3 Social Factors

  • 6.4 Technological Factors

  • 6.5 Environmental Factors

  • 6.6 Legal Factors

7. Technology and Innovation Landscape

  • 7.1 AI-Enabled Image Analysis and Automated Segmentation (Convolutional Neural Networks – CNNs; GANs for Image Reconstruction)

  • 7.2 Deep Learning for SPECT and PET Image Denoising, Reconstruction, and Quantification

  • 7.3 Quantitative Imaging and SUV Calculation Tools (Standardized Uptake Value – SUV for PET)

  • 7.4 Kinetic Modeling and Parametric Imaging Software for Tracer Pharmacodynamics

  • 7.5 Radiomics and AI-Based Quantification Tools for Tumor Biology Characterization

  • 7.6 Dosimetry Software for Targeted Radionuclide Therapy (Lu-177, Ra-223, Y-90, I-131) — DOSIsoft PLANET, Hermes Hermia

  • 7.7 Multimodality Fusion Software: PET/CT, SPECT/CT, PET/MRI Image Co-registration

  • 7.8 Radiopharmacy Management Software: Isotope Inventory, Dispensing, Quality Control, Regulatory Compliance

  • 7.9 PACS Integration and DICOM Compliance Tools for Enterprise Nuclear Medicine Workflows

  • 7.10 Cloud-Native Nuclear Medicine Platforms: SaaS Deployment, Remote Access, and Real-Time Collaboration (Radiology Partners RPX AI–AWS HealthImaging, November 2023)

  • 7.11 PSMA PET/CT AI Quantification Platforms (PYLARIFY AI — Lantheus Holdings, FDA-Cleared 2021)

  • 7.12 Cardiac PET Software and AI-Powered Coronary Artery Disease (CAD) Assessment (Bracco HeartSee v4.0)

  • 7.13 GE HealthCare MIM Encore: AI-Integrated PET and SPECT Reporting Platform (June 2025)

  • 7.14 Spectrum Dynamics VERITON-CT + Hermes Hermia Integrated SPECT Dosimetry Platform (April 2024)

8. Market Segmentation Analysis

8.1 By Software Type

  • 8.1.1 Patient Data Management Software (Dominant: 29.1% Share in 2026)

  • Electronic Patient Records Integration

  • Imaging Data Storage and Retrieval

  • Regulatory Audit Trail and Compliance Management

  • 8.1.2 Imaging and Visualization Software

  • 2D/3D/4D Image Rendering and Multi-Planar Reconstruction (MPR)

  • Multimodality Image Fusion and Co-registration (PET/CT, SPECT/CT, PET/MRI)

  • Advanced Visualization for Oncology, Cardiology, and Neurology

  • 8.1.3 Image Processing and Analysis Software (Largest by Product Type: 32% Share in 2024)

  • SPECT Image Processing and Analysis

  • PET Image Processing and Analysis

  • Hybrid Imaging Processing (PET/CT, SPECT/CT, PET/MRI)

  • 8.1.4 Analysis and Quantification Software (Fastest-Growing: 10.80% CAGR)

  • SUV Calculation and Quantitative Assessment Tools

  • Kinetic Modeling and Parametric Imaging

  • Radiomics and AI-Based Quantification

  • 8.1.5 Clinical Decision Support Software (CDSS)

  • 8.1.6 Dosimetry Software

  • Patient-Specific Dosimetry for RLT (Lu-177, Y-90, Ra-223, I-131)

  • Multi-Radionuclide Dosimetry Platforms (DOSIsoft PLANET, Hermes Hermia)

  • 8.1.7 Workflow and Scheduling Software

  • Patient Scheduling, Order Tracking, and Appointment Management

  • Nuclear Medicine Department Operations Workflow

  • 8.1.8 Treatment Planning Software

  • Radiopharmaceutical Therapy Planning Modules

  • Radiation Safety and Shielding Calculation Tools

  • 8.1.9 Radiopharmacy Management Software

  • Isotope Inventory Management

  • Quality Control and Regulatory Compliance Modules

  • Order Tracking and Dispensing Management

  • 8.1.10 Others (AI and Advanced Analytics Software, PACS Integration Tools, Cloud-Based Data Sharing Platforms)

8.2 By Modality

  • 8.2.1 Positron Emission Tomography (PET) Software (Dominant: 38.8% Share in 2026; Fastest-Growing: 10.60% CAGR)

  • PET/CT Software

  • PET/MRI Software

  • 8.2.2 Single Photon Emission Computed Tomography (SPECT) Software (Largest Modality: 46% Share in 2024)

  • SPECT/CT Software

  • Planar Scintigraphy Software

  • 8.2.3 Hybrid Imaging Software (PET/CT, SPECT/CT, PET/MRI)

  • 8.2.4 Others (Planar Scintigraphy, Gamma Camera Systems)

8.3 By Deployment Mode

  • 8.3.1 On-Premises (Dominant: 41% Share in 2024 — Data Control and HIPAA/GDPR Compliance Driver)

  • 8.3.2 Cloud-Based / Web-Based (Fastest-Growing: 11.20% CAGR — Scalability and Remote Access Driver)

  • 8.3.3 Hybrid Deployment

8.4 By Integration Complexity

  • 8.4.1 Standalone Software Solutions

  • 8.4.2 Integrated Software Solutions (HIS, PACS, RIS, EHR Integration)

8.5 By Pricing Model

  • 8.5.1 Subscription-Based Pricing (SaaS)

  • 8.5.2 Perpetual License Pricing

  • 8.5.3 Usage-Based Pricing (Pay-Per-Use)

  • 8.5.4 Freemium or Trial-Based Pricing

  • 8.5.5 Customized or Enterprise Pricing

8.6 By Therapeutic Area (Application)

  • 8.6.1 Oncology (Dominant: 44% Share in 2024; 34.5% Share in 2026)

  • 8.6.2 Cardiology (Myocardial Perfusion, Cardiac PET Software)

  • 8.6.3 Neurology (Fastest-Growing: 10.50% CAGR; Alzheimer's, Parkinson's, Epilepsy Imaging)

  • 8.6.4 Endocrinology (Thyroid Imaging, Adrenal Gland Scanning)

  • 8.6.5 Gastroenterology

  • 8.6.6 Others (Orthopedics, Nephrology, Infectious Disease Imaging)

8.7 By End User

  • 8.7.1 Hospitals and Clinics (Dominant: 47% Share in 2024; Healthcare Providers Segment: 9.2% CAGR)

  • 8.7.2 Diagnostic Imaging Centers (Fastest-Growing: 10.30% CAGR)

  • 8.7.3 Academic and Research Institutions

  • 8.7.4 Pharmaceutical and Biotechnology Companies

  • 8.7.5 Radiopharmacies

9. Regional Market Analysis

9.1 North America

  • 9.1.1 Market Overview and Growth Outlook (Dominant Region: 38–43.3% Share in 2024–2026)

  • 9.1.2 United States (USD 286.39 Million in 2025; FDA 510(k) Innovation Framework; GE HealthCare, Lantheus, MIM Software, INVIA)

  • 9.1.3 Canada (Nordion Isotope Infrastructure; Healthcare IT Modernization Programs)

9.2 Europe

  • 9.2.1 Market Overview (EU MDR CE Mark Compliance; GDPR-Driven Data Security Investment; ESNM Conferences)

  • 9.2.2 Germany (Largest European Market; Siemens Healthineers, Sun Nuclear/Mirion; EU MDR Sun Nuclear CE IIb, April 2022)

  • 9.2.3 United Kingdom (Claritas NucMed Technologies Ltd. Spin-Off, July 2024; NHS Digital Transformation)

  • 9.2.4 France (DOSIsoft PLANET Onco Dose FDA 510(k) Clearance, March 2025; EU MDR CE Mark)

  • 9.2.5 Italy (COMECER S.p.A. Radiopharmacy Software; Bracco Imaging S.p.A. HeartSee v4.0)

  • 9.2.6 Spain

  • 9.2.7 Russia

  • 9.2.8 Rest of Europe

9.3 Asia-Pacific

  • 9.3.1 Market Overview (Fastest-Growing Region: 11.60% CAGR; 24.5% Share in 2026)

  • 9.3.2 China (Healthy China 2030; Neusoft Medical Systems SPECT/CT; NMPA Regulatory Modernization)

  • 9.3.3 Japan (PMDA; Canon Medical Systems; Fujifilm Holdings Nuclear Medicine Software)

  • 9.3.4 India (AIIMS New Delhi–SAMEER MOU for Medical Electronics Innovation, March 2025; CDSCO; Abbott Ultreon AI Software India Launch, October 2023)

  • 9.3.5 South Korea (Samsung Healthcare; DuchemBio Nuclear Medicine Software Development)

  • 9.3.6 Australia (ANSTO Nuclear Medicine Infrastructure; Pacific Healthcare IT Partnerships)

  • 9.3.7 ASEAN Countries

  • 9.3.8 Rest of Asia-Pacific

9.4 Latin America

  • 9.4.1 Market Overview

  • 9.4.2 Brazil (CNEN Radioisotope Infrastructure; Hospital IT Software Modernization)

  • 9.4.3 Argentina

  • 9.4.4 Mexico

  • 9.4.5 Rest of Latin America

9.5 Middle East

  • 9.5.1 Market Overview (GCC Digital Health Investments; Israeli MedTech Ecosystem)

  • 9.5.2 GCC Countries (Saudi Arabia, UAE, Kuwait)

  • 9.5.3 Israel (NovaBay, Camero Tech, Medical Imaging Innovation Hub)

  • 9.5.4 Rest of Middle East

9.6 Africa

  • 9.6.1 Market Overview

  • 9.6.2 South Africa (NTP Radioisotopes; SAFARI-1 Reactor Support)

  • 9.6.3 North Africa

  • 9.6.4 Central Africa

10. Competitive Landscape

  • 10.1 Market Concentration and Competitive Overview (Top 3 Players: GE HealthCare 20–25%, Siemens Healthineers 15–20%, Philips 8–10%; Combined 70–80% Share)

  • 10.2 Market Share Analysis of Top Players (2025) — Company Evaluation Matrix (Star, Emerging Leaders, Innovators)

  • 10.3 Competitive Benchmarking Matrix

  • 10.4 Key Strategic Developments

  • 10.4.1 Mergers and Acquisitions (GE HealthCare–MIM Software Acquisition, January 2024; Lantheus–EXINI Diagnostics PYLARIFY AI Platform)

  • 10.4.2 Product Launches and FDA / CE Mark Milestones (GE HealthCare MIM Encore Launch, June 2025; Hermes Hermia Platform Update, May 2025; DOSIsoft PLANET Onco Dose v3.2 FDA 510(k) Clearance, March 2025; Bracco HeartSee v4.0, March 2026)

  • 10.4.3 Research Partnerships and Collaborations (Spectrum Dynamics–Hermes Medical Solutions VERITON+Hermia Integration, April 2024; SNMMI–Ancora.ai AI Trial Finder Platform, August 2025; Radiology Partners RPX AI–AWS HealthImaging, November 2023)

  • 10.4.4 Geographic Expansion and Strategic Investments in Emerging Markets

  • 10.5 Innovation and R&D Pipeline Analysis

  • 10.5.1 AI-Integrated PET/SPECT Platforms in Active Development

  • 10.5.2 Multi-Radionuclide Dosimetry Software (SIRT, MRT, I-131, Lu-177)

  • 10.5.3 Cloud-Native Nuclear Medicine Workflow SaaS Platforms in Pipeline

  • 10.6 Patent Landscape and Intellectual Property Trends in Nuclear Medicine Software

  • 10.7 Vertical Integration Trends: OEM–Software Bundling Strategies (GE HealthCare, Siemens, Philips, Canon Medical)

  • 10.8 ESG and Radiation Safety Compliance Practices Embedded in Software Solutions

11. Company Profiles

(The final report includes a complete list of companies)

11.1 GE HealthCare Technologies Inc. (MIM Software Inc.)

  • 11.1.1 Company Overview

  • 11.1.2 Financial Performance

  • 11.1.3 Product Portfolio

  • 11.1.4 Strategic Initiatives

  • 11.1.5 SWOT Analysis

11.2 Siemens Healthineers AG

11.3 Koninklijke Philips N.V. (Philips Healthcare)

11.4 Canon Medical Systems Corporation

11.5 Bracco Imaging S.p.A.

11.6 Hermes Medical Solutions AB

11.7 Lantheus Holdings, Inc. (EXINI Diagnostics AB)

11.8 Mirion Technologies, Inc. (ec2 Software Solutions / Sun Nuclear)

11.9 Mirada Medical Ltd. (Oxford Instruments)

11.10 PMOD Technologies LLC

11.11 Mediso Medical Imaging Systems Ltd.

11.12 DOSIsoft SA

11.13 INVIA Medical Imaging Solutions

11.14 Segami Corporation

11.15 Sofie Biosciences Inc.

12. Investment and Opportunity Analysis

  • 12.1 High-Growth Segments and Investment Hotspots (AI Dosimetry Software, Cloud-Native Platforms, Theranostics Workflow Software)

  • 12.2 Venture Capital and Private Equity Activity in Nuclear Medicine Software and Healthcare IT

  • 12.3 Government and Institutional Funding (NIH NCI, DOE Isotope Program, IAEA Technical Cooperation, Horizon Europe)

  • 12.4 Emerging Business Models: SaaS Licensing, OEM Software Bundles, Usage-Based Pay-Per-Scan Models, and CDMO Partnerships

  • 12.5 Strategic Recommendations for Market Stakeholders

13. Impact Analysis

  • 13.1 Impact of AI and Machine Learning on Nuclear Medicine Image Analysis Accuracy and Clinical Workflow Efficiency

  • 13.2 Impact of FDA/EU MDR Regulatory Approvals on Software Innovation Pace and Market Confidence (DOSIsoft, Bracco, Sun Nuclear)

  • 13.3 Impact of COVID-19 on Nuclear Medicine Procedure Volumes, Software Procurement, and Cloud Adoption

  • 13.4 Impact of Radiopharmaceutical Therapy Growth (Pluvicto, Lutathera) on Downstream Dosimetry and Therapy Planning Software Demand

  • 13.5 Impact of Global Healthcare Data Interoperability Standards (FHIR, DICOM, HL7) on Nuclear Medicine Software Integration

14. Appendix

  • 14.1 List of Tables

  • 14.2 List of Figures

  • 14.3 Research Methodology Overview

  • 14.4 Data Sources and References

  • 14.5 Glossary of Key Terms (PET, SPECT, PACS, RIS, DICOM, SUV, SaMD, CDSS, SaaS, RLT, DOTATATE, PSMA, dosimetry, radiomics, CNNs, GANs, FHIR, HL7, MDR, 510(k), etc.)

  • 14.6 About the Publisher

15. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.